These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 16404346)

  • 1. Activation of antitumor cytotoxic T lymphocytes by fusion of patient-derived dendritic cells with autologous osteosarcoma.
    Yu Z; Ma B; Zhou Y; Zhang M; Qiu X; Fan Q
    Exp Oncol; 2005 Dec; 27(4):273-8. PubMed ID: 16404346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dendritic cells fused with human cancer cells: morphology, antigen expression, and T cell stimulation.
    Koido S; Ohana M; Liu C; Nikrui N; Durfee J; Lerner A; Gong J
    Clin Immunol; 2004 Dec; 113(3):261-9. PubMed ID: 15507391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic tumor vaccine produced by electrofusion between osteosarcoma cell line and dendritic cells in the induction of antitumor immunity.
    Yu Z; Ma B; Zhou Y; Zhang M; Long H; Wang Y; Fan Q
    Cancer Invest; 2007; 25(7):535-41. PubMed ID: 17952746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of cytotoxic T lymphocytes against human cancer cell lines using dendritic cell-tumor cell hybrids generated by a newly developed electrofusion technique.
    Imura K; Ueda Y; Hayashi T; Itoh T; Shimizu K; Tamai H; Yano Y; Naito K; Kohara J; Nakane K; Matsuura Y; Takeda A; Takeda T; Kawai K; Yamagishi H
    Int J Oncol; 2006 Sep; 29(3):531-9. PubMed ID: 16865268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficient activation of autologous tumor-specific T cells: a simple coculture technique of autologous dendritic cells compared to established cell fusion strategies in primary human colorectal carcinoma.
    Draube A; Beyer M; Schumer S; Thomas RK; von Tresckow B; Koslowsky TC; Krieglstein CF; Schultze JL; Wolf J
    J Immunother; 2007; 30(4):359-69. PubMed ID: 17457211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specific antitumor effects of tumor vaccine produced by electrofusion between osteosarcoma cell and dendritic cell in rats.
    Yu Z; Fan Q; Hao X; Long H
    Cell Mol Immunol; 2004 Dec; 1(6):454-60. PubMed ID: 16293215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
    Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y
    Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antitumor efficacy of fusion cells from esophageal carcinoma cells and dendritic cells as a vaccine in vitro].
    Deng YJ; Xia JC; Zhou J; Wang QJ; Zhang PY; Zhang LJ; Rong TH
    Ai Zheng; 2007 Feb; 26(2):137-41. PubMed ID: 17298741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of specific cytolytic T lymphocytes using fusions of hepatocellular carcinoma (HCC) patient-derived dendritic cells and allogeneic HCC cell line.
    Yin XY; Wang L; Lu MD; Li BJ; Huang JF
    Hepatogastroenterology; 2008; 55(81):155-9. PubMed ID: 18507097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficient CTL productivity of modified fusion cells by increase of heat shock protein 70.
    Koide T; Iinuma H; Fukushima R
    Oncol Rep; 2009 Mar; 21(3):737-46. PubMed ID: 19212634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Killing activity of cytotoxic T lymphocytes stimulated by dendritic cell vaccine loaded with autologous cervical cancer antigen].
    Zhou CJ; Ma W; Zhou JD; Zhao YX; Xie HQ
    Ai Zheng; 2006 Feb; 25(2):143-7. PubMed ID: 16480575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction of expression vector of hTERT- hIL18 fusion gene and induction of cytotoxic T lymphocyte response against hTERT.
    Tong XM; Zheng SE; Bader A; Yao HP; Wu NP; Altmeyer P; Brockmeyer NH; Jin J
    Eur J Med Res; 2008 Jan; 13(1):7-14. PubMed ID: 18226991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of fusion cells from patient-derived ovarian carcinoma cells and dendritic cells as a vaccine for clinical use.
    Koido S; Nikrui N; Ohana M; Xia J; Tanaka Y; Liu C; Durfee JK; Lerner A; Gong J
    Gynecol Oncol; 2005 Nov; 99(2):462-71. PubMed ID: 16137749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dendritic cells fused with allogeneic breast cancer cell line induce tumor antigen-specific CTL responses against autologous breast cancer cells.
    Zhang Y; Ma B; Zhou Y; Zhang M; Qiu X; Sui Y; Zhang X; Ma B; Fan Q
    Breast Cancer Res Treat; 2007 Nov; 105(3):277-86. PubMed ID: 17187233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immunogenic reactivity of CTLs induced by electrofusion cells of human dendritic cells and gastric cancer cells].
    Imura K; Hayashi T; Yano Y; Naito K; Kouhara J; Ueda Y; Nakane K; Matsuura Y; Takeda A; Takeda T; Kawai K; Yamagishi H
    Gan To Kagaku Ryoho; 2004 Oct; 31(11):1797-9. PubMed ID: 15553719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Inducing specific antitumor effects on osteosarcoma by fused vaccine of rat dendritic cells].
    Yu Z; Fan QY; Ma BA; Hao XB; Long H
    Ai Zheng; 2005 Mar; 24(3):285-91. PubMed ID: 15757528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and gammadelta T cells.
    Schnurr M; Scholz C; Rothenfusser S; Galambos P; Dauer M; Röbe J; Endres S; Eigler A
    Cancer Res; 2002 Apr; 62(8):2347-52. PubMed ID: 11956095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A dendritic cell based hybrid cell vaccine generated by electrofusion for immunotherapy strategies in HNSCC.
    Weise JB; Maune S; Görögh T; Kabelitz D; Arnold N; Pfisterer J; Hilpert F; Heiser A
    Auris Nasus Larynx; 2004 Jun; 31(2):149-53. PubMed ID: 15121224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced antitumor immunity derived from a novel vaccine of fusion hybrid between dendritic and engineered myeloma cells.
    Hao S; Bi X; Xu S; Wei Y; Wu X; Guo X; Carlsen S; Xiang J
    Exp Oncol; 2004 Dec; 26(4):300-6. PubMed ID: 15627063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma.
    Raje N; Hideshima T; Davies FE; Chauhan D; Treon SP; Young G; Tai YT; Avigan D; Gong J; Schlossman RL; Richardson P; Kufe DW; Anderson KC
    Br J Haematol; 2004 May; 125(3):343-52. PubMed ID: 15086415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.